Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Leases (2021 - 2025)

Vivos Therapeutics has reported Current Leases over the past 5 years, most recently at $55000.0 for Q4 2025.

  • Quarterly Current Leases fell 88.47% to $55000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55000.0 through Dec 2025, down 88.47% year-over-year, with the annual reading at $55000.0 for FY2025, 88.47% down from the prior year.
  • Current Leases was $55000.0 for Q4 2025 at Vivos Therapeutics, roughly flat from $55000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $654000.0 in Q2 2025 and troughed at $55000.0 in Q3 2025.
  • The 5-year median for Current Leases is $447000.0 (2023), against an average of $391235.3.
  • Year-over-year, Current Leases skyrocketed 481.94% in 2022 and then crashed 88.66% in 2025.
  • A 5-year view of Current Leases shows it stood at $72000.0 in 2021, then skyrocketed by 481.94% to $419000.0 in 2022, then grew by 13.13% to $474000.0 in 2023, then increased by 0.63% to $477000.0 in 2024, then crashed by 88.47% to $55000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Leases are $55000.0 (Q4 2025), $55000.0 (Q3 2025), and $654000.0 (Q2 2025).